Patient preferences for atopic dermatitis treatments: a discrete choice experiment

References

• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):1–8.
   Web of Science ®Google Scholar
• Whiteley J, Emir B, Seitzman R, et al. The burden of atopic dermatitis in US adults: results from the 2013 National Health and Wellness Survey. Curr Med Res Opin. 2016;32(10):1645–1651.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498.
   PubMed Web of Science ®Google Scholar
• Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol. 2015;135(4):984–991.
   PubMed Web of Science ®Google Scholar
• Beikert FC, Langenbruch AK, Radtke MA, et al. Willingness to pay and quality of life in patients with atopic dermatitis. Arch Dermatol Res. 2014;306(3):279–286.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40.
   PubMed Web of Science ®Google Scholar
• Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: end of the drought? J Allergy Clin Immunol. 2017;140(3):633–643.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Thyssen JP, Fahrbach K, et al. Comparative ­efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35(9):1797–1810.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168.
   PubMed Web of Science ®Google Scholar
• Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333–1343.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Silverberg JI, Nosbaum A, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693–707.
   PubMed Web of Science ®Google Scholar
• Waldman RA, DeWane ME, Sloan B, et al. Characterizing dupilumab facial redness: a multi-institution retrospective medical record review. J Am Acad Dermatol. 2020;82(1):230–232.
   PubMed Web of Science ®Google Scholar
• Gargiulo L, Ibba L, Cortese A, et al. Real-life effectiveness and safety of upadacitinib in adults and adolescents with moderate-to-severe atopic dermatitis: a single-center 16-week study. Dermatol Ther. 2023;13(2):651–660.
   PubMed Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a Real-Life French Multicenter Adult Cohort. J Am Acad Dermatol. 2019;81(1):143–151.
   PubMed Web of Science ®Google Scholar
• Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023.
   Google Scholar
• Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. 2022;102:adv00677.
   PubMed Web of Science ®Google Scholar
• Uchiyama A, Fujiwara C, Inoue Y, et al. Real-world effectiveness and safety of baricitinib in Japanese patients with ­atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469–471.
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. A study to learn about the study medicine (called abrocitinib) in adult patients with moderate to severe atopic dermatitis: NCT05250115; 2023 [cited 2023 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT05250115
   Google Scholar
• Clinicaltrials.gov. A study to learn about the study medicine (called Cibinqo) in people with atopic dermatitis: NCT05391061; 2023 [cited 2023 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT05391061
   Google Scholar
• Clinicaltrials.gov. BioDay registry: data collection regarding the use of new systemic treatment options in patients with atopic dermatitis: NCT03549416; 2023 [cited 2023 Apr 3]. Available from: https://clinicaltrials.gov/ct2/show/NCT03549416
   Google Scholar
• Soekhai V, de Bekker-Grob EW, Ellis AR, et al. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201–226.
   PubMed Web of Science ®Google Scholar
• Carrascosa Carrillo JM, Baselga Torres E, Gilaberte Calzada Y, et al. Quantifying physician preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. Dermatol Ther. 2022;12(5):1197–1210.
   Web of Science ®Google Scholar
• Okubo Y, Ho KA, Fifer S, et al. Patient and physician preferences for atopic dermatitis injection treatments in Japan. J Dermatolog Treat. 2020;31(8):821–830.
   PubMed Web of Science ®Google Scholar
• Boeri M, Sutphin J, Hauber B, et al. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatolog Treat. 2022;33(3):1449–1458.
   PubMed Web of Science ®Google Scholar
• Thomas C, Raibouaa A, Wollenberg A, et al. Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment. BMJ Open. 2022;12(8):e058799.
   PubMed Web of Science ®Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health – a checklist: a report of the ISPOR good research practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403–413.
   PubMed Web of Science ®Google Scholar
• Reed Johnson F, Lancsar E, Marshall D, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health. 2013;16(1):3–13.
   PubMed Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300–315.
   PubMed Web of Science ®Google Scholar
• Hensher DA, Rose JM, Greene WH. Applied choice analysis. Cambridge (UK): Cambridge University Press; 2005.
   Google Scholar
• Tan J, Linos E, Sendelweck MA, et al. Shared decision making and patient decision aids in dermatology. Br J Dermatol. 2016;175(5):1045–1048.
   PubMed Web of Science ®Google Scholar
• van der Kraaij GE, Vermeulen FM, Smeets PMG, et al. The current extent of and need for shared decision making in atopic dermatitis and psoriasis in The Netherlands: an online survey study amongst patients and physicians. J Eur Acad Dermatol Venereol. 2020;34(11):2574–2583.
   PubMed Web of Science ®Google Scholar